Evidence map›Paper›PMID 39611484›Full record

ArticleOncology reports2025

Potential of epithelial membrane protein 3 as a novel therapeutic target for human breast cancer.

Yi-Wen Wang, Yih-Lin Tuan, Jiu-Yao Wang, Hong-Yi Chang, Chien-An Chu, Yi-Lin Chen, Hui-Wen Chen, Chung-Liang Ho, Chung-Ta Lee, Nan-Haw Chow

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yi-Wen WangDepartment of Food Safety Hygiene and Risk Management, College of Medicine, National Cheng Kung University, Tainan 701401, Taiwan, R.O.C.
Yih-Lin TuanInstitute of Molecular Medicine, College of Medicine, National Cheng Kung University, Tainan 701401, Taiwan, R.O.C.
Jiu-Yao WangCenter for Allergy, Immunology, and Microbiome, China Medical University Hospital, China Medical University, Taichung 404327, Taiwan, R.O.C.
Hong-Yi ChangDepartment of Anatomy, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807378, Taiwan, R.O.C.
Chien-An ChuDepartment of Food Safety Hygiene and Risk Management, College of Medicine, National Cheng Kung University, Tainan 701401, Taiwan, R.O.C.
Yi-Lin ChenDepartment of Medical Laboratory Science and Biotechnology, College of Medicine, National Cheng Kung University, Tainan 701401, Taiwan, R.O.C.
Hui-Wen ChenDepartment of Pathology, National Cheng Kung University Hospital, Tainan 701401, Taiwan, R.O.C.
Chung-Liang HoDepartment of Food Safety Hygiene and Risk Management, College of Medicine, National Cheng Kung University, Tainan 701401, Taiwan, R.O.C.
Chung-Ta LeeDepartment of Food Safety Hygiene and Risk Management, College of Medicine, National Cheng Kung University, Tainan 701401, Taiwan, R.O.C.
Nan-Haw ChowDepartment of Food Safety Hygiene and Risk Management, College of Medicine, National Cheng Kung University, Tainan 701401, Taiwan, R.O.C.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Amplification of human epidermal growth factor 2 receptor (HER2) and overexpression of estrogen receptor (ER) and/or progesterone receptor (PR) are key determinants in the treatment planning for human breast cancer (BC). Currently, targeted therapies for BC are focused mainly on these biomarkers. However, development of resistance to targeted drugs is almost unavoidable, emphasizing the importance of biochemical and pharmaceutical advances to improve treatment outcomes. To the best of our knowledge, the present study is the first to show functional crosstalk

Indexed as

Breast NeoplasmsCell ProliferationErb-b2 Receptor Tyrosine KinasesMembrane GlycoproteinsXenograft Model Antitumor AssaysAdultAgedAnimalsBiomarkers, TumorCell Line, TumorCell MovementDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionErbB ReceptorsFemaleGene Expression Regulation, NeoplasticBiomarkers, TumorEMP3 protein, humanERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesErbB ReceptorsMembrane GlycoproteinsReceptors, EstrogenReceptors, ProgesteroneTrastuzumabbreast carcinomaEMP3estrogen receptorHER familyprogesterone receptortherapy

Identifiers

PMID39611484
PMCPMC11632653

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.